Real-world evidence has the potential to be especially valuable in a number of healthcare use cases MORE

BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company’s total funds raised to over $200 million MORE

As patients now assume the role of health consumer, they rationally expect retail-level experiences with greater first-dollar payment for health insurance, health care services and medical products like prescription drugs. In the past couple of months, Amazon announced many health-related plans and developments, including: Accepting medical and health savings accounts (HSAs) to pay for consumer health products like over-the-counter drugs. MORE

AI/Machine Learning Ambulatory Analytics/Big Data C-Suite Leadership Clinical Communication and Patient Experience EMR-EHR Health IT Company Healthcare IT Hospital - Health System IT Drug Development Healthcare AI Healthcare IT Today Survey Machine Learning Personalized Medicine Predictive Analytics Radiology AI Smart Exam Rooms Treatment Pathways Virtual Office Assistants MORE

But key facets of its business didn’t develop as planned, say people familiar with the company. It had hoped to sell analytics to pharmaceutical companies as they increasingly incorporated genetic sequencing into drug development, these people say. Human Longevity Inc. raced to a billion-dollar plus valuation on the hopes that it could apply advances in genomics to improve medicine. MORE

Blockchain was first developed as a means of transaction for the digital currency Bitcoin. Blockchain technology’s potential impact on the life sciences industry (drug development, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain. One can envision how blockchain might also stop drug counterfeiting thereby improving patient safety. MORE

An important part of advancing medical research and drug development is making participation in clinical trials easier and more inclusive. To develop treatments that work on men, women, and children of all ages and different ethnicities we need to have clinical trial data that represents our diverse population. MORE

We spoke with Tommy Ritz, MBA, and Dr. Jason McDevitt, William & Mary’s Tech Transfer Director about Auxulin – [link] – the company they founded to market a new drug that alleviates hyperglycemic episodes. . patents to drugs in the development pipeline. The solution they found is a variation of a prescription drug that is off-patent and not widely used. Technically, this is a new use of an old drug,” McDevitt said. “We’re MORE

A drug prescription can come with a lot of questions. With our “Know Your Drugs” series, we provide you with a snapshot of the different diabetes drugs on the market, and links to additional information. Metformin is currently the most popular drug prescribed for those with Type 2 diabetes. It is considered a generally safe and effective drug for lowering blood sugar levels, and it’s one of the first diabetes medications prescribed after diagnosis. MORE

BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), today unveiled an artificial intelligence (AI) platform for monitoring and predicting the progression of neurodegenerative diseases for the purpose of identifying markers for personalised patient care and improved drug development MORE

Startup Medicare Advantage insurer Clover Health has launched a new drug development subsidiary called Clover Therapeutics. MORE

From streamlining operations to fine-tuning optimal treatments, the technology makes a business case for pharma MORE

Dubbed Clover Therapeutics, the unit's first project will be a partnership with Genentech targeting ocular diseases among senior populations MORE

For example, it’s unclear whether the disease can spread before a person develops symptoms or whether people who never become symptomatic can still spread the disease. Seeking Treatment : Currently, there is no drug available to cure the disease, but many drug developers are working on a reliable antiviral to directly target the coronavirus. Around the world, the newest coronavirus outbreak has millions of people concerned about their health. MORE

Valo Health’s Opal Computational Platform uses machine learning, cloud computing and real-world data to assist in the drug discovery and development process MORE

The study’s authors urge policymakers to support the development of new strategies to prevent infections and to support innovative antibiotic drug development A new study finds that antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient. Multiply that by the estimated number of antibiotic-resistant infections, and costs run well over $2 billion per year. MORE

The company's drug development CRO, Covance, will integrate Medable's software to expand its decentralized trial capabilities MORE

The thought of gathering massive amounts of data, from claims to EHR to molecular and making it easily accessible for drug development research once seemed impossible, as did getting at previously 'undruggable' pathways that defied the effects of even the most innovative drugs. Now, with the advent of immuno-oncology, the oncology field is poised to take advantage of these advances to enable the development of precise therapies that match the right drug to the right patient. MORE

Companies News deep learning drug development protein characterization verily deepmassVerily’s DeepMass, a deep-learning application for mass spectrometry, is highly accurate at predicting peptide mass spectra, according to a manuscript. The post Verily’s Deep-Learning Model Accurately Characterizes Proteins appeared first on MedTech Boston. MORE

This legislation boosts funding to the National Institutes of Health and establishes an innovation grant fund to “accelerate the discovery, development, and delivery” of new treatments and therapies. New drug and device development has become so prohibitively expensive that few manufacturers can shoulder the development cost from idea to pivotal clinical trial or even raise the necessary capital in the financial markets. MORE

AI and drug developmentWhere’s the telehealth rule? — MORE

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline. In October, FierceBiotech reported that the company pulled the plug on the development of evacetrapib, a drug meant to ward off heart attacks and strokes, after investing $90 million in costly clinical trials. MORE

Interestingly, the future of DTx may lie in cooperation rather than in competition with Big Pharma and drug development. Introduction While progress in medicine continues to astound us, it hides a modus operandi that hasn’t changed for decades – a bricks and mortar model of delivering healthcare reactively to treat illness and disease. Although highly lucrative for healthcare providers and Big Pharma, it is archaic, capital intensive and, in many ways, broken. MORE

The Clinical One platform enables data to be shared across phases and the various functions involved in drug development, as data can be entered once for use in multiple areas, including: Randomization and Supplies Management. A better, faster, more cost-effective way to bring drugs to market to the millions of patients who are waiting with hope.”. This will require us to transform our processes and how systems and departments interact throughout the drug development cycle. MORE

CVC’s recent acquisition of the women’s health division of the Israeli drug developer Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Silicon Valley Bank, Zinc.vc and The Up Group recently hosted a breakfast on ‘Female Health Innovation’, often known as FemTech. The event brought together the ecosystem of founders, investors, scaled organisations and advisors and was chaired by Nooman Haque, MD at Silicon Valley Bank. MORE

Of the 50,000 drug overdose deaths that occurred in 2015, roughly 33,000 of them were caused by opioids. One of the more widely accepted solutions to this epidemic is providing access to alternate forms of pain management, which is where MMJ BioScience’s innovative new FDA cannabis drug development comes into play. The current state of America’s opioid crisis is one of uncertainty and peril if we are to not make a change sooner than later. MORE

The Digital Therapeutics Alliance developed a definition to differentiate DTx solutions from health and wellness apps. The ReSET Prescription Digital Therapeutic (PDT), developed in collaboration with Sandoz, treats patients with Substance Use Disorder (SUD). The second milestone was when Pear signed a collaboration deal with Novartis to co-develop digital therapeutics for schizophrenia and multiple sclerosis in March 2018. MORE

Francesca is responsible for developing and executing an end-to-end company-wide digital transformation. Francesca has over 20 years of drug development and healthcare expertise in both the US and Europe, and most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund and previously held roles at Novartis and Mount Sinai school of medicine, just to name a few. MORE

In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugs developed to treat Type 2 diabetes. This was the first research ( release ) on using this Type 2 approved drug for T1D treatment and there were larger confirmatory studies ( release ) in 2016 and 2018. The study will supplement insulin therapy with these two drugs designed to treat Type 2 Diabetes or with semaglutide alone. “ MORE

He’s also a pioneer in changing the way we go about developing drugs to treat people with rare diseases, and, in so doing, he’s managed to put his own condition into remission, and help many others as well. As an engineer and business leader, I've worked to develop, launch and scale innovative products and solutions that impact health and wellness. Podcast business of health drug development drug discovery rare diseases USA MORE

“These technologies can also be leveraged by pharmaceutical companies to monitor the results of the drugs developed by them," said Ashish Kaul, technical insights senior research analyst at Frost & Sullivan. which uses AI and signal processing to measure patients’ vitals via a smartphone’s camera, and Tytocare which has developed a device that patients can use at home during a teleconsultation to measure vital signs. MORE

For example, it’s unclear whether the disease can spread before a person develops symptoms or whether people who never become symptomatic can still spread the disease. Seeking Treatment : Currently, there is no drug available to cure the disease, but many drug developers are working on a reliable antiviral to directly target the coronavirus. Around the world, the newest coronavirus outbreak has millions of people concerned about their health. MORE

We found in human and mouse research that defects in white blood cells causing disease had a signaling pathway that we could drug. We looked for generic drugs that stimulate TNF. The Bacillus Calmette–Guerin (BCG) vaccine is a microorganism developed as a vaccine for tuberculosis (TB) more than 100 years ago and has also been used as therapy for bladder cancer for the last 40 years. The Hygiene Hypothesis was developed in the UK in the 1960s. MORE

The FDA declined to approve Zynquista a drug developed by Sanofi SA and Lexicon Pharmaceuticals intended for use with insulin in patients with Type 1 Diabetes. The generic name of the drug is sotagliflozin. The decision comes about two months after an FDA advisory panel divided over whether the once-daily oral drug should be approved as an add-on to insulin therapy. The post FDA Rejects SGLT Drug Zynquista for T1D Use appeared first on Insulin Nation. MORE

In an interview with the Wall Street Journal, Narasimhan pointed to some of the investments the company has made into the cutting-edge areas of drug development, such as gene therapy and radiopharmaceuticals. Food and Drug Administration for Kymriah, a genetically-modified autologous T-cell immunotherapy. The deal for AveXis followed a licensing and supply deal with Spark Therapeutics to develop and commercialize Spark’s gene therapy Luxturna outside the U.S. MORE

Countries such as India, Singapore, China, Korea, Spain and Israel have successfully developed and deployed indigenous mobile apps to provide instant notifications if an exposure to a covid infected person has occurred. Artificial Intelligence for Monitoring and Drug Development. AI and cloud computing are being used extensively to identify potential drugs and augment the research for coronavirus vaccine development. MORE

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline. In October, FierceBiotech reported that the company pulled the plug on the development of evacetrapib, a drug meant to ward off heart attacks and strokes, after investing $90 million in costly clinical trials. MORE

As many know, the pharmaceutical industry is heavily regulated and specialized, with slow drug-development timelines, strict processes and quality requirements, and rigid silos. This article is copyrighted strictly for Electronic Health Reporter. Illegal copying is prohibited. MORE